Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Panels Favor Advair, Symbicort Over Single-Entity LABAs For Asthma

Executive Summary

Three FDA advisory committees recommended the withdrawal of asthma indications for two long-acting beta agonists - GlaxoSmithKline's Serevent (salmeterol) and Novartis's Foradil (formoterol) -during a Dec. 11 meeting

You may also be interested in...



Foradil Completes LABAs’ Exit From Risk Evaluation and Mitigation Strategies

FDA says Novartis’ assessment of the long-acting beta agonist’s REMS, which consisted only of a communication plan, shows the “plan, and therefore the REMS, has met its goal.”

Patient Voice Missing In Asthma Drug Safety Debate – FDA’s Jenkins

When a post-marketing safety signal arises, patients’ perspective of benefit is often drowned out by consumer advocates’ worries about a drug’s risks, the Office of New Drugs director says.

AstraZeneca’s Symbicort On Advair’s Heels With COPD Approval

Symbicort's rapid onset of action and lack of pneumonia signal could be competitive advantages as the drug enters the market with its newly approved use for chonic obstructive pulmonary disease

Related Content

UsernamePublicRestriction

Register

PS050443

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel